---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000055"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:17:17.881129+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BeiGene shareholders approve equity plan share increases and director re-elections at AGM

## Summary
- Approved Third Amended 2016 Share Option Plan, adding 92.82M shares to the reserve.
- Approved Fourth Amended 2018 ESPP, increasing share availability by 5.07M shares.
- Re-elected Class II directors Brandicourt, Glazer, Goller, Sanders with strong support.
- Approved general mandates to issue up to 20% and repurchase up to 10% of shares.
- Approved RSUs and PSUs to CEO John Oyler ($6M each) and other executive grants.

## SEC filing metadata
- accession: 0001651308-24-000055
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000055/0001651308-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000055/bgne-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000055
- JSON: https://secwatch.observer/filing/0001651308-24-000055.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.